Albireo Pharma (ALBO) Upgraded to “Sell” at BidaskClub

Albireo Pharma (NASDAQ:ALBO) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Saturday, August 4th.

Other analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Albireo Pharma from a “hold” rating to a “buy” rating and set a $36.00 target price for the company in a report on Tuesday, July 24th. Wedbush reaffirmed an “outperform” rating on shares of Albireo Pharma in a report on Monday, July 16th. Jefferies Financial Group began coverage on shares of Albireo Pharma in a research report on Friday, April 20th. They set a “buy” rating and a $50.00 price target on the stock. Finally, ValuEngine raised shares of Albireo Pharma from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $59.40.

Shares of Albireo Pharma traded down $0.59, reaching $31.20, during midday trading on Friday, MarketBeat Ratings reports. The company had a trading volume of 27,868 shares, compared to its average volume of 46,566. The firm has a market cap of $379.63 million, a P/E ratio of -9.90 and a beta of 1.23. Albireo Pharma has a 1-year low of $20.25 and a 1-year high of $39.87.

Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.24). The company had revenue of $0.73 million for the quarter, compared to analyst estimates of $2.00 million. equities analysts anticipate that Albireo Pharma will post -3.36 earnings per share for the current fiscal year.

In related news, COO Jan Mattsson sold 25,000 shares of the business’s stock in a transaction on Wednesday, June 13th. The shares were sold at an average price of $32.26, for a total value of $806,500.00. Following the sale, the chief operating officer now directly owns 43,538 shares of the company’s stock, valued at approximately $1,404,535.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.60% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of ALBO. Wells Fargo & Company MN increased its stake in Albireo Pharma by 282.1% in the 4th quarter. Wells Fargo & Company MN now owns 6,350 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 4,688 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Albireo Pharma in the 4th quarter valued at $216,000. Millennium Management LLC increased its stake in Albireo Pharma by 65.4% in the 4th quarter. Millennium Management LLC now owns 46,594 shares of the biopharmaceutical company’s stock valued at $1,193,000 after buying an additional 18,425 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in Albireo Pharma in the 1st quarter valued at $1,869,000. Finally, Birchview Capital LP acquired a new stake in Albireo Pharma in the 1st quarter valued at $782,000. 55.21% of the stock is currently owned by institutional investors and hedge funds.

Albireo Pharma Company Profile

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Read More: Market Capitalization in the Stock Market

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply